What are the indications, dosing regimens, and safety considerations for 5‑fluorouracil (5‑FU)?

5-Fluorouracil (5-FU): Indications, Dosing, and Safety

5-Fluorouracil is the backbone of colorectal cancer chemotherapy and is FDA-approved for topical treatment of actinic keratoses and superficial basal cell carcinomas, with systemic formulations used primarily in combination regimens (FOLFOX or FOLFIRI) for metastatic colorectal cancer. 1, 2, 3

Primary Indications

Systemic (Intravenous) 5-FU

Colorectal Cancer is the primary indication where 5-FU demonstrates mortality benefit:

• First-line metastatic disease: Combination chemotherapy with 5-FU/leucovorin/oxaliplatin (FOLFOX) or 5-FU/leucovorin/irinotecan (FOLFIRI) provides superior response rates, progression-free survival, and overall survival compared to 5-FU/LV alone 4, 2
• Adjuvant therapy: Perioperative FOLFOX for resectable liver metastases improves progression-free survival by 7-8% at 3 years 4
• Potentially resectable metastases: Combination chemotherapy is the preferred option when objective response is the primary goal for surgical resection 4

Breast Cancer: 5-FU is used in anthracycline-based regimens (AC or EC), though data show 5-FU can be dropped from these regimens without loss of efficacy 5

Topical 5-FU

FDA-approved indications 3:

• Multiple actinic/solar keratoses (2.5% or 5% strength)
• Superficial basal cell carcinomas (5% strength only) when conventional methods are impractical

Off-label dermatologic uses with supporting evidence 6, 7:

• Squamous cell carcinoma in situ
• Ano-genital warts (0.5% with salicylic acid 10%)
• Keloids (intralesional injection)

Dosing Regimens

Systemic Chemotherapy for Colorectal Cancer

FOLFOX Regimen 1, 8:

• Oxaliplatin 85 mg/m² IV day 1
• Leucovorin 400 mg/m² (or levo-leucovorin 200 mg/m²) IV over 2 hours day 1
• 5-FU 400 mg/m² IV bolus day 1, then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46-48 hours) continuous infusion
• Repeat every 2 weeks
• Critical safety note: NCCN recommends limiting orders to 24-hour units (1200 mg/m²/day NOT 2400 mg/m² over 48 hours) to minimize medication errors 1

FOLFIRI Regimen 1:

• Irinotecan 180 mg/m² IV day 1
• Leucovorin 400 mg/m² IV over 2 hours day 1
• 5-FU 400 mg/m² IV bolus, then 1200 mg/m²/day × 2 days continuous infusion
• Repeat every 2 weeks

Simplified Biweekly Infusional 5-FU/LV (sLV5FU2) 1:

• Leucovorin 400 mg/m² IV over 2 hours day 1
• 5-FU 400 mg/m² IV bolus, then 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46-48 hours) continuous infusion
• Repeat every 2 weeks

Roswell-Park Regimen 1:

• Leucovorin 500 mg/m² IV over 2 hours, days 1,8,15,22,29,36
• 5-FU 500 mg/m² IV bolus 1 hour after leucovorin start, same days
• Repeat every 8 weeks

FOLFOXIRI (for highly selected cases with potentially resectable metastases) 1:

• Irinotecan 165 mg/m² IV day 1
• Oxaliplatin 85 mg/m² day 1
• Leucovorin 400 mg/m² day 1
• 5-FU 3200 mg/m² over 48-hour continuous infusion starting day 1
• Repeat every 3 weeks
• Caution: Concerns about toxicity limit use to highly selected cases 4

Topical Dosing

Actinic Keratoses 3:

• Apply 5% solution twice daily to cover lesions
• Continue until inflammatory response reaches erosion stage (usually 2-4 weeks)
• Complete healing may take 1-2 months after cessation

Superficial Basal Cell Carcinomas 3:

• Apply 5% solution twice daily to cover lesions
• Continue for at least 3-6 weeks, may require up to 10-12 weeks
• Apply with non-metal applicator or glove; wash hands immediately if applied with fingers

Key Safety Considerations

Toxicity Profile Differences by Route and Schedule

Infusional regimens are generally less toxic than bolus regimens 4, 9, 2:

Infusional 5-FU toxicity 2:

• Hand-foot syndrome (palmar-plantar erythrodysesthesia)
• Mucositis
• Diarrhea
• Less myelosuppression than bolus

Bolus 5-FU toxicity 4:

• Myelosuppression (primary concern)
• Mucositis
• Diarrhea

Combination regimen-specific toxicity 4, 2:

• FOLFIRI: More alopecia, febrile neutropenia, and diarrhea
• FOLFOX: More polyneuropathy (cumulative with oxaliplatin)

High-Risk Populations

Age and Sex Considerations 10:

• Patients >70 years experience relatively increased toxicity
• Female patients demonstrate greater toxicity than males
• North American patients experience greater fluoropyrimidine toxicity than European patients, requiring lower capecitabine doses 1, 8

DPYD Genotype and Dose Adjustment

DPYD variants cause severe, potentially fatal 5-FU toxicity 11:

The NCCN panel does not recommend universal pretreatment DPYD genotyping at this time due to:

• Uncertainty about which variants confer risk
• Potential impact of dose reductions on efficacy (particularly in adjuvant setting)
• Evidence that dose reduction for c.1236G>A variant carriers showed shorter PFS (HR 1.43, P=0.007) 11

However, if DPYD testing is performed:

• Heterozygous carriers: Reduce starting dose by 25-50% depending on variant
• Poor metabolizers: Avoid fluoropyrimidines
• Monitor closely and adjust doses based on toxicity in first 2 cycles

Systemic Absorption from Topical Use

Topical 5-FU has minimal systemic absorption 3:

• Studies show 0.76% average recovery in urine over 3 days
• Approximately 5-6% of topical dose absorbed systemically
• Twice daily application results in 5-6 mg systemic absorption per 100 mg daily dose
• Negligible plasma levels detected

Treatment Duration and Maintenance

For metastatic colorectal cancer 4:

• Treatment until progression or toxicity is standard
• Treatment interruptions or de-escalation can be considered if cumulative toxicity occurs and disease control is achieved
• Maintenance with fluoropyrimidine alone prolongs progression-free survival compared to complete treatment break after initial combination chemotherapy 4
• Reintroduce combination chemotherapy upon progression

Sequential vs. Combination Therapy

Sequential therapy starting with fluoropyrimidine monotherapy is a valid option in selected frail patients, as combination chemotherapy was not superior for overall survival in FOCUS and CAIRO studies 4, 9. However:

• Combination chemotherapy remains preferred when objective response is the goal (e.g., for surgical resection or symptomatic metastases) 4, 9
• Approximately 15% of patients today receive initial fluoropyrimidine monotherapy 9, 2
• Exposure to all three cytotoxics (fluoropyrimidines, oxaliplatin, irinotecan) in various sequences results in longest survival 4

Common Pitfalls to Avoid

1. Medication error risk: Always order 5-FU continuous infusions in 24-hour units (1200 mg/m²/day) rather than total dose over 48 hours to prevent overdosing 1, 8

2. Geographic dosing differences: European capecitabine doses (1000 mg/m² twice daily) may be too high for North American patients; consider starting at 850 mg/m² twice daily 1, 8

3. Topical application technique: Use non-metal applicator or gloves; metal can inactivate 5-FU 3

4. Premature discontinuation: For topical use in actinic keratoses, continue until erosion stage is reached, not just erythema 3

5. Inadequate follow-up: For superficial basal cell carcinomas, follow patients for reasonable period to confirm cure, as success rate is ~93% vs. nearly 100% for surgery 3